Biocompatibility of silicone-coated oxygenator in cardiopulmonary bypass.
BACKGROUND
This study was designed to analyze the biocompatibility of silicone-coated oxygenators using inflammatory response as the outcome measure, and to investigate whether the silicone-coated oxygenators perform better in terms of postoperative organ dysfunction.


METHODS
The 32 patients who underwent cardiopulmonary bypass (CPB) were divided into 3 groups: group A (n = 10), heparin-coated circuit with silicone-coated oxygenator; group B (n = 11), whole heparin-coated circuit; and group C (n = 11), whole untreated circuit. The plasma concentrations of the proinflammatory markers, made of inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, interleukin-8), terminal complement complex (C5b-9), and polymorphonuclear elastase (PMN-E), were measured by enzyme-linked immunosorbant assay.


RESULTS
All proinflammatory markers were significantly lower in groups A and B than in group C, especially C5b-9 and PMN-E concentrations, which were significantly lower in group A than in group B. The alveolar-arterial oxygen gradients (A-aDO2) and the respiratory index were significantly better in group A than in group C. In group B, however, only the A-aDO2 was significantly better than in group C. The duration of intubation and the length of stay in the intensive care unit stay were significantly shorter in groups A and B than in group C.


CONCLUSIONS
Silicone-coated oxygenators are biocompatible and prevent postoperative organ dysfunction.
Shimamoto
A
A
Department of Thoracic and Cardiovascular Surgery, Mie University School of Medicine, Tsu, Japan. jj6jdv@clin.medic.mie-u.ac.jp
Kanemitsu
S
S
Fujinaga
K
K
Takao
M
M
Onoda
K
K
Shimono
T
T
Tanaka
K
K
Shimpo
H
H
Yada
I
I
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D015938:Complement Membrane Attack Complex / Q000032:analysis; D001026:Coronary Artery Bypass; D003422:Critical Care; D004867:Equipment Design; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007442:Intubation, Intratracheal; D007902:Length of Stay; D019272:Leukocyte Elastase / Q000097:blood; D008297:Male; D008875:Middle Aged; D010106:Oxygenators; D011446:Prospective Studies; D011659:Pulmonary Gas Exchange / Q000502:physiology; D012119:Respiration; D012828:Silicones; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000517:prevention & control; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000925:Anticoagulants; D020099:Coated Materials, Biocompatible; D015938:Complement Membrane Attack Complex; D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D012828:Silicones; D014409:Tumor Necrosis Factor-alpha; D006493:Heparin; D019272:Leukocyte Elastase